Skip to content
DataLookout
Menu

GYNETNCT04652076

GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab

StatusCompleted
PhasePhase 1/2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial completed Show 4 more changesShow less
    • Trial status changed: Unknown → Active, Not Recruiting
    • Study completion date changed from estimate of Dec 31, 2026 to Nov 16, 2026
    • Study completion pushed from Jul 30, 2026 to Dec 31, 2026
    • Enrollment target: estimated 240 to confirmed 238
  2. Notable Eligibility criteria expanded, about 30 words Show 4 more changesShow less
    • Study completion date: Jul 30, 2026 to Dec 31, 2026
    • Secondary endpoints: details revised at 1 of 11 entries
    • Site details revised at 2 of 15 sites
    • Collaborators: details revised at 1 of 2 entries
  3. Minor Changed Registry marked status Unknown; last known: Active, Not Recruiting
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 15 of 15 sites
    v10
  5. Notable Primary completion date: Oct 30, 2024 to Oct 30, 2025
    • Study completion date: Jul 30, 2025 to Jul 30, 2026
    v9
Show 7 earlier versionsHide 7 earlier versions
  1. Notable Primary completion date: Oct 25, 2023 to Oct 30, 2024
    • Study completion date: Nov 25, 2024 to Jul 30, 2025
    v8
  2. Notable Primary completion date: Oct 25, 2022 to Oct 25, 2023
    • Study sites: 12 to 15
    v7
  3. Minor Site contacts updated at 1 of 12 sitesv6
  4. Notable Eligibility criteria expanded, about 43 wordsv5
  5. Notable Primary completion date: Oct 25, 2021 to Oct 25, 2022
    • Study sites: 6 to 12
    v4
  6. Notable Eligibility criteria expanded, about 40 words
    • Study sites: 4 to 6
    • Primary completion date: Jun 25, 2021 to Oct 25, 2021
    v3
  7. Notable Trial status: Not Yet Recruiting to Recruiting
    • Eligibility criteria expanded, about 50 words
    • Study sites: 0 to 4
    • Start date changed from estimate of Nov 25, 2020 to Dec 14, 2020
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

DLT occurrence
Timeframe: Safety run in Period: At the end of Cycle 2 (each cycle is 21 days) for the first 6 to 12 patients per arm
Overall response Rate (ORR)
Timeframe: At 3 months of treatement and then every 12 weeks, up to 2 years

Secondary (11)

Clinical Benefit Rate (CBR)
Duration of Response
Progression-free Survival
Overall Survival
Best Overall Response
Show 6 moreShow less
Pharmacokinetic parameter: Cmax
Pharmacokinetic parameter: tmax
Pharmacokinetic parameter: AUCt
Pharmacokinetic parameter: AUC∞
Pharmacokinetic parameter: CL
Pharmacokinetic parameter: t1/2

Arms and interventions

Arm A: Standard Chemotherapy alone (Paclitaxel + Carboplatin)Other

Standard Chemotherapy will be adminitred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma

Arm B: Experimental double combination [Standard Chemotherapy +NP137]Other

Experimental double combination \[Standard Chemotherapy +NP137\] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma

Arm C: Experimental double combination [Pembrolizumab +NP137]Other

Experimental double combination \[Pembrolizumab +NP137\] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma

Arm D: Experimental triple therapeutical combination [Pembrolizumab+ Standard Chemotherapy + NP137]Other

Experimental triple combination \[Pembrolizumab+ Standard Chemotherapy + NP137\] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma

Drugs: NP137, Pembrolizumab, Paclitaxel, Carboplatin

Sites

15 sites in 1 country